NLRP3 and metabolic dysfunction-associated steatotic liver disease: In mouse models of NASH, administration of a selective NLRP3 inhibitor suppressed caspase-1 and IL-1β accumulation, and limited the development of fibrosis [162], suggesting that the inflammasome plays a key role in mediating the progression of NAFLD.